ceo on con call says comparison to corresponding quarter valid due to seasonality, which makes sense given christmas break and summer holidays in Aus
suggests that there is more revenue to come from existing 12 sites in the US as more doctors use the product and presumably as they ramp up proceedures with the aeroform device, this bodes well for sales as they roll out to 120 sites by Q3
defining early 17 success as dozens of unit sales, mid 17 in hundreds of unit sales and by end of 17 in thousands
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.684M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 29583410 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 59394450 | 39 |
View Market Depth
| Last trade - 16.13pm 20/06/2025 (20 minute delay) ? |
| AXP (ASX) Chart |
Day chart unavailable